Project Grant HT94252310603

The Defense Health Agency awarded Yale University a 3-year, USD 1,277,053 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to target the chromatin regulator WDR5 to treat breast cancer metastasis. The project aims to advance the understanding and development of novel therapeutic approaches for breast cancer, a leading cause of cancer-related deaths. As the prime awardee, Yale University will conduct the research, development, and testing activities...

The U.S. Defense Health Agency awarded a $1,213,276 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2023 through August 31, 2026, will fund research on the role of vascular mimicry in the outgrowth of dormant melanoma micrometastases. The goal of this research is to transform health care for Service Members and the American public through innovative and impactful medical research on solutions...

The Defense Health Agency has awarded a $1,674,999.00 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). The grant is for the "PERTURBOMICS IDENTIFICATION OF CRITICAL GENETIC TARGETS IN NK CELLS FOR BREAST CANCER THERAPY" project, which will be conducted from September 1, 2023 to August 31, 2026. The funding will support basic, applied, and advanced biomedical research to transform healthcare for service members and the public...

The Defense Health Agency awarded a $670,917 project grant to Yale University under the Military Medical Research and Development (CFDA 12.420) federal grant program. The purpose of the 2-year grant, with a performance period from June 2025 to June 2027, is to conduct research on exploiting METTL3 inhibition to dysregulate DNA repair as a treatment for leukemia. This project grant supports advanced biomedical research initiatives focused on transforming healthcare for military service members...

The Yale University was awarded a $753,749 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from March 2022 through March 2025 to target replication stress in triple-negative breast cancer. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care...

The Defense Health Agency awarded Yale University a $3,129,087.00 Project Grant on September 1, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant supports advanced research to develop integrative platforms for cellular immunotherapies against resistant hematopoietic malignancies and solid tumors. Key aims include targeting combinations of gene editing and CAT inhibition to enhance CAR-T cell function, and investigating gene editing coupled with CAT...

The Defense Health Agency awarded Yale University a $837,500 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "MECHANISM-CENTRIC PREDICTIVE MODELING FOR PROSTATE CANCER". The 3-year grant, running from July 1, 2024 to June 30, 2027, supports Yale's work to develop new predictive modeling approaches for prostate cancer. This research aims to improve understanding of the underlying biological mechanisms driving prostate cancer...

The Yale University was awarded a $1,244,745 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2021 to June 2025 to overcome resistance to EGFR inhibitors in advanced head and neck cancers. The Military Medical Research and Development program supports biomedical research to transform military and public health care through innovative solutions. This award will further...

This federal Project Grant award of $837,497.00 was issued by the Defense Health Agency to Yale University, effective November 1, 2024 through October 31, 2027. The grant is funded under the Military Medical Research and Development (CFDA 12.420) program, which supports advanced biomedical research initiatives to transform healthcare for military service members and the broader public. Under this award, Yale University will conduct research focused on "Feeding Stress Primes the Pancreas for...

This Project Grant award from the Defense Health Agency, through the Military Medical Research and Development program (CFDA 12.420), provides $514,335 to Yale University to optimize adoptive cellular immunotherapy for rare melanomas. The award began on September 1, 2023 and is scheduled for completion on August 31, 2026. The research aims to transform health care for service members and the American public through innovative and impactful medical solutions, with a focus on developing treatments...